197 related articles for article (PubMed ID: 17498906)
21. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
22. Long-term complete remission of metastatic adrenocortical carcinoma.
Cárdenas-Salas J; Castelo B; Regojo RM; González-Sanchez JA; Álvarez-Escolá C
Horm Mol Biol Clin Investig; 2023 Mar; 44(1):67-71. PubMed ID: 36069780
[TBL] [Abstract][Full Text] [Related]
23. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
24. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
25. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
26. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
27. [A long term survival of the patient treated due to advanced adrenocortical carcinoma].
Bednarek-Tupikowska G; Florczak A; Witkiewicz W; Tupikowski W; Cisarz E
Pol Arch Med Wewn; 2005 May; 113(5):462-5. PubMed ID: 16479829
[TBL] [Abstract][Full Text] [Related]
28. [Surgical treatment of hormone-producing adrenocortical carcinoma with liver metastases].
Nermoen I; Foss A; Holte H; Mathisen Ø; Brekke IB; Line PD; Bergan A
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3061-3. PubMed ID: 15586188
[TBL] [Abstract][Full Text] [Related]
29. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
30. Discussion.
J Am Coll Surg; 2016 Apr; 222(4):490-2. PubMed ID: 27016977
[No Abstract] [Full Text] [Related]
31. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
Veytsman I; Nieman L; Fojo T
J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
[TBL] [Abstract][Full Text] [Related]
32. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
Schwarte S; Brabant EG; Bastian L; Bruns F
Anticancer Res; 2007; 27(4A):1917-20. PubMed ID: 17649795
[TBL] [Abstract][Full Text] [Related]
33. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
Advani A; Vaikkakara S; Gill MS; Arun CS; Pearce SH; Ball SG; James RA; Lennard TW; Bliss RD; Quinton R; Johnson SJ
J Clin Pathol; 2008 Aug; 61(8):939-44. PubMed ID: 18515402
[TBL] [Abstract][Full Text] [Related]
34. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
Kasperlik-Załuska AA; Migdalska BM; Zgliczyński S; Makowska AM
Cancer; 1995 May; 75(10):2587-91. PubMed ID: 7736405
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
36. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
37. [Features of clinical presentation of malignant adrenocortical tumor cortex metabolism over time].
Kvacheniuk AM
Lik Sprava; 2003 Dec; (8):52-4. PubMed ID: 14965007
[TBL] [Abstract][Full Text] [Related]
38. Metastatic congenital adrenocortical carcinoma: a case report with tumor remission at 3 1/2 years.
Godil MA; Atlas MP; Parker RI; Priebe CJ; Zerah MM; Kane P; Tsung J; Wilson TA
J Clin Endocrinol Metab; 2000 Nov; 85(11):3964-7. PubMed ID: 11095414
[TBL] [Abstract][Full Text] [Related]
39. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]